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A study on improvement of quality of life after esophageal stenting in 
carcinoma of esophagus. 
Abstract 
The main aim of palliation in patients with inoperable esophageal cancer is to 
relieve dysphagia with acceptable morbidity and mortality, and thus improve 
quality of life (QOL). The use of a self-expanding metal stent (SEMS) is a well-
established modality for palliation of dysphagia in such patients. In our study 
assessed the QOL after palliative stenting in patients with inoperable esophageal  
cancer. Twenty one patients with dysphagia due to inoperable esophageal cancer 
underwent SEMS insertion between september 2014 and September  2015 in 
Coimbatore Medical College Hospital. All patients had grade III/IV dysphagia 
(n=21),   In our study  the procedural success rate was around  95% out of 21 
patients only one patient had the complication of stent migration, which needed 
reinsertion.  
           In our study, the relief of dysphagia , general health related improvement of 
quality of life,and pain related improvement of quality of life were studied with the 
help of EORTC QLQ 30 OES 18 questionnaire,in addition to this we have studied 
and compared the anthropometric improvement like BMI, Biochemical 
improvement like, Hemoglobin ,Total proteins ,and other liver function tests, 
SGOT,SGPT , before and after stenting. 
  The dysphagia score is 6.10+1.48 before stenting ,it improved to 12.57+2.29 after 
1 week,15.05+1.74,after 4 weeks and 15.57 +1.20 after 8 weeks.Thus the 
improvement of dysphagia before and after stenting is  statistically significant.  
   The personal social health related quality of life score before stenting was 
32.95+2.24, it improved to 26.33+3.56, after one week ,15.05 +2.22 after 4 weeks 
and 13.14+1.98 after 8 weeks. The improvement of health related quality of life is 
also statistically significant. 
The pain related quality of life was 7.10+1.54 before stenting, after one week the 
pain got worsened and it increased to 10.00+1.97 .The worsening of pain after one 
week is statistically significant .After 4 weeks the pain related quality of life 
improved from the baseline score before stenting to 5.38,and after 8 weeks it 
further improved to 4.00+0.95,These improvements in pain related quality of life 
too are statistically significant. 
The improvement of BMI and Hemoglobin  4 weeks after stenting is statistically 
not significant , but  8 weeks after stenting , the improvement of  BMI and 
hemoglobin are statistically significant 
           The biochemical parameters like Blood sugar, Urea are within the normal 
limits except for the diabetic patients, but the variation is statistically significant , 
before Vs 4 weeks and 8 weeks after stenting.   
           The variation in the creatinine values before and after stenting is not 
significant. 
           A statistically significant improvement is noted in the values of the total 
proteins and albumin measured at 4 weeks and 8 weeks post stenting, whereas the 
globulin improvement became significant only after 8 weeks. 
          No statistically significant changes are noted in the values of liver function 
tests like total bilirubin and SGOT, but SGPT values are found to be  increased 
with statistically significant  values, 8 weeks after stenting. 
 
Key words – Esophageal stenting, SEMS, Quality of life after stenting,carcinoma 
of esophagus. 
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INTRODUCTION 
 
 Esophageal carcinoma is one among the  diseases with  lowest five 
year survival rate27,the average being only around 10 – 15 %.Only one third 
of the patients with carcinoma esophagus  present with resectable disease at 
the time of diagnosis27,2. 
 
  Majority of the patients have a fatal outcome, Where the main cause 
of morbidity in patients with advanced or locally advanced carcinoma 
esophagus is severe dysphagia2,1, that negatively affect their nutritional 
status, cachexia due to carcinoma as well as  dysphagia leads to the  weight 
loss . 
 
  The important aim of  treatment in patients with inoperable esophageal 
carcinoma  is to relieve   dysphagia with minimum acceptable  morbidity and 
mortality, and thus  to  improve their quality of life.  
 
 Placement of a Self Expanding Metallic Stent has become the 
preferred  treatment modality for the palliation of  dysphagia due to 
carcinoma esophagus, because it is a  minimal invasive procedure that does 
not need any major anesthesia and can be done with application of local 
anesthetics with or without iv sedation, while other surgical procedures like  
feeding jejunostomy and feeding gastrostomy, require major anaesthetic 
interventions. 
 
 
 
 Non surgical procedures like Nasogastric tube placement and feeding 
through them does not improve dysphagia and are poorly tolerated by the 
patients. The other treatment modalities to improve the nutrition like 
TPN(Total paraenteral nutrition) are usually avoided because of increased 
infection rates ,higher costs  and TPN cannot be used  for long period of time 
. 
 The SEMS are gaining more popularity because the procedure is easy 
to perform, non invasive, and has no anesthesia related complications , 
 
 Dysphagia is relieved almost immediately after The Self expanding 
metallic stent placement. In most of the  researches and studies, that were 
conducted to study the outcome of improvement in quality of life after 
placement of Self expanding metallic stent  in patients with carcinoma 
esophagus, dysphagia relief is the only indicator used in  measuring the 
improvement of quality of life, while other indicators  that can affect general 
health and the health related quality of life of the patients ,including  the 
physical, mental and social wellbeing of the patients and the biomedical 
parameters, before and after the stent placement were not adequately 
explored. Keeping this point in our mind ,In this study we evaluated not only 
the  improvement of dysphagia  after stenting , but also  the pain, health  
related quality of life(HRQOL) improvement along with the  improvement 
and changes of various other health related indicators , biochemical 
parameters that  can affect the quality of life were studied and evaluated by a 
questionnaire, intervention and laboratory based results and analysis . 
 
 
AIMS AND OBJECTIVES: 
 To characterize  patients posted for stenting as palliative measure 
for  dysphagia  due to carcinoma of esophagus    
 
 To compare quality of life of patients with carcinoma of 
esophagus with dysphagia before and after esophageal stenting 
 
 To evaluate clinical predictors of improved quality of life after 
stenting . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 Carcinoma esophagus  is  the sixth most common cancer in the world1 
.The carcinoma esophagus is a disease of mid and late adulthood2with a poor 
survival rate ,it is an extremely aggressive and fatal cancer27 disease that is  
least studied. It has very poor 5 year survival rate (around 10 %) according 
to some literatures and some text books. Studies27 suggest  that the survival 
rate could be  much lower than 10 % , Carcinoma of  the esophagus is  
seventh leading cause of death due to malignancies .The most common  
pathologic types, are squamous cell carcinoma and adenocarcinoma.  
 
 The incidence of carcinoma esophagus   accounts for one percent of 
all malignancies and  six percent of all the Gastro intestinal malignancies . 
Worldwide, squamous cell cancer is most common, but adenocarcinoma is 
nowadays more often diagnosed  in the western world. Its incidence is  rising 
in those countries27.This may be due to the life style change occurring over 
past few decades ,including changing food habits, obesity due to sedentary 
life style, which are in turn  the risk factors of GERD1,2,27. 
 
Geographical variation in oesophageal cancer: 
 The incidence of esophageal carcinoma is different it varies  for 
different area and countries, Which  is the unique feature of carcinoma 
esophagus .The change is  more when compared with other cancers2. 
Squamous cell cancer is seen endemic in  South Africa in its region called  
 
 
Transkei and  also widely seen in The Asian ‘cancer belt’ that area starting 
from the  middle of Asia,  from the  Caspian Sea (Iran northern region) to 
China2. The highest incidence rate in the world is in the Henan province 
located in China particularly in a place called Linxian2.,Most deaths have 
occurred there due to carcinoma esophagus which even became, a single 
leading cause of death. More than 100 cases per 100 000population are 
diagnosed there per year2, The specific cause of carcinoma of esophagus  in 
those  endemic areas is not clearly known, but it is suspected that it may be 
due to a combination of contamination of food  with some fungi and  
deficiencies in several nutrients It is noted that in certain  areas, the 
supplementation of the food with certain nutrients ,including selenium, 
vitamin E, and beta carotene resulted in the decrease in the incidence of the 
disease2,1. 
 
 But drinking alcoholic beverages , hot food , consumption of tobacco 
in any form, including chewable or smoked are the main risk factors in 
certain others other areas for the occurrence of squamous cell carcinoma. 
Incidence rates vary from less than five per 100000 in the white people in  
USA to, 26 :100 000 in some areas of  France. 
 
 In India the incidence rate widely varies from state to state28 ,it is 
highest in the state Kashmir  about 70/100000. In Mumbai it accounts for 
20/100000,whereas in Bangalore it is 11/100000. Highest Female : male 
 
 
(more than 5 per 100,000 person-years) were reported from Bombay, in 
India; Shanghai, in China28; and in some regions of united kingdom. The 
disease is often seen  rising  with age, reaching its  peak in the sixth to 
seventh decade of life2,1. 
 
 World wide  ratio ,Male : Female = 3.5 : 1 .In The United States2, and  
many other Western Nations, the incidence is now increasing.  in the past 
few decades with a more profound increase in the  incidence rates of 
adenocarcinoma, Though the squamous cell carcinoma  predominates all 
over the world.  
 
 Though it is appropriate  to plan   the  treatment  according to their 
pathologic types of  malignancy,  still they are mostly treated  like single 
entity2. Todays treatment interventions have limited effect  on the  survival, 
and  the case fatality rate nears almost  90%. Though carcinoma esophagus is 
diagnosed increasingly after the widespread use of upper GI endoscopy1,2 , 
the disease is often inoperable and the main aim of the treatment is palliation 
rather that a curative one2,1,27 
 
 A study conducted at Coimbatore Medical College Hospital , 
Coimbatore, India in the year 2013 revealed out of 50 patients evaluated 
with endoscopy for dysphagia , 16 patients were found to have carcinoma 
esophagus .Among those 16 patients curative esophagectomy was possible in 
 
 
only one .Rest were treated with non surgical procedures, including stenting 
and chemotherapy. 
Anatomy of the esophagus 
 Esophagus is the muscular tube extending from the base of pharynx at 
C 6 to the cardia of stomach at T 11 .It is about 25 to 30 cm length and 
average inner luminal diameter of 23 to 30 mm. Esophagus  has got three 
parts  cervical, thoracic and abdominal, as it passes a through the above 
region in its course. Total length of the esophagus is also divided as upper, 
middle and lower third, roughly 8 cm each in surgical anatomy. 
 
 The cervical esophagus starts from cricopharyngeus and extend upto 
horizontal part of inferior constrictor muscle. Trachea and recurrent 
laryngeal nerve are the main structures related to cervical part. Thoracic 
esophagus starts from the right side but it deviates to the left side and 
continues as abdominal part. It is related to azygos vein, thoracicduct, 
aorta,pleura and pericardium. 
 
 In neck and thorax it is related to vertebral column posteriorly and 
trachea anteriorly. At the carina, heart and pericardium lie directly anterior to 
the thoracic esophagus. Upper esophageal sphincter and lower esophageal 
sphincter are the two high pressure zones in cranial and caudal part of 
esophagus respectively. Esophagus enters the abdominal cavity through the 
 
 
esophageal opening in the diaphragm at the level of T10. Along its course 
the esophagus has  three constrictions , First one is the narrowest point at 
cricopharynx,  which has 14 mm inner diameter. It is the narrowest part of 
the gastro  intestinal tract and situated 15 cm from the upper incisor . 
 
 Second esophagus constriction is broncho aortic constriction at the 
level of T4,  situated roughly at 25 cms from the upper incisor, It is also the 
commonest site of perforation during endoscopic procedures. The third 
constriction is diaphragmatic constriction  at the point where it enters the 
abdomen at T10 level and 40 cm from the upper incisor. 
Fig.1 Esophagus divisions 
 
 
 
 
Blood supply of the esophagus: 
 Cervical part of the esophagus is supplied by  Inferior thyroid artery. 
Thoracic part  is supplied by direct branches of aorta and the esophageal 
branches of bronchial arteries, Supplemented by inferior thyroid artery, 
intercostal arteries and inferior phrenic arteries. 
 Abdominal part of the esophagus derives its blood supply from  left 
gastric artery and Inferior phrenic artery, Esophageal branches in  this part 
either arise  from inferior phrenic or celiac trunk. All the arteries  form a 
capillary network that continues along the full length of the  esophagus 
within the submucous layer.  
 
  
 
 
Fig 2.Arteries  of esophagus. 
 
Venous drainage of the esophagus: 
 Submucous venous plexus, which extends through the whole length of 
the esophagus is the  first basin for venous drainage. 
 
 
 
 
 
 Cervical part of esophagus is drained by Azygos vein on the right side. 
Abdominal part of the esophagus is drained by Left and right phrenic  veins 
of systemic circulation and Left gastric and short gastric veins of   portal 
circulation. 
 
 Venous system of the esophagus in its lower end is one of the junction 
of the portal and systemic circulation. 
 
Fig 3 .Veins  of esophagus 
 
 
 
Lymphatic drainage of the esophagus 
 
 Interconnecting lymphatic plexus in the submucous and muscular 
layer of the  esophagus drains in to the regional nodes. Because of the 
longitudinal arrangement of  the lymphatics, spread to the distant nodes 
occurs early in case of carcinoma of  esophagus. 
Cervical part of the esophagus drains in to   
 Paratracheal nodes anteriorly 
 Deep cervical laterally 
 Internal jugular posteriorly 
 Carcinomas of the cervical and upper third of the thoracic esophagus 
drain  into the cervical and superior mediastinal lymph nodes 
Thoracic esophagus drains in to 
 Mediastinal nodes 
 Thoracic duct 
 Paratrachealnodes 
 Subcapital nodes 
 Paraesophageal nodes 
 Retrocardiac nodes 
 Infracardiac nodes 
 Para aortic nodes 
  Inferior pulmonary ligament nodes 
 
 
The knowledge of lymphatic drainage of esophagus is very important 
because, the surgical approaches for esophageal cancer are based on the  
anatomy of   the lymphatic drainage of  esophagus. That is  why some 
specific surgical procedure is recommended , based on the cancer site in the 
esophagus . 
Fig 4.Lymph vessels and Nodes of esophagus. 
 
 
 
 
 
 
 
 
Innervations of the esophagus : 
 Autonomic nervous system innervates the esophagus like it does to the 
other  parts of gastro intestinal tract for the motility and the secretion 
functions. 
Sympathetic innervation. 
 Sympathetic innervation has inhibitory action on esophagealmotility 
and  excitatory action on its sphincters. Superior ganglion of the cervical 
sympathetic trunk innervates the cervical  esophagus. 
 The upper part of the Thoracic esophagus is innervated by the stellate  
ganglion of cervical sympathetic trunk ,the lower part is innervated by lesser  
splanchnic ganglion . 
 The Abdominal part of the esophagus is innervated by the sympathetic 
fibers along the left gastric artery. 
Parasympathetic innervation. 
 Vagus nerve provides the parasympathetic innervation for motility and  
secretory functions and has inhibitory effect on sphincters . Two plexus of 
nerves known as Auerbach’ smyentric and Submucous Meissner’splexus , 
are very sparse in the esophagus as compared to other parts of  the  Gastro 
Intestinal Tract. 
  
 
 
Fig.5 Nerves of esophagus. 
 
 
Esophagus Histology 
Esophagusis  predominantly composed of muscular tissue 
Esophagus has the following layers 
 Mucosa 
 Basement membrane 
 Lamina propria  
 Muscularis mucosa 
 Submucosa  
 Muscularispropria 
 Advential layer   
 
 
 
 
Fig.6.Esophageal wall. 
 
Mucosal Layer 
 Inner most layer of the esophagus is the mucosal layer. It is lined by  
squamous epithelium except in the distal 1 or 2 cm where it is replaced by  
transitional or junctional columnar cella at the Z line. 
 Epithelium, basement membrane ,laminapropria and the 
muscularismucos are the parts of mucosal layer. 
Submucosa 
 Submucosa is deeper to the mucosa and it contains lymphatics, 
vascular structures ,mucous glands and Meissner’s plexus of nerves. 
Muscular Layer 
 There are  two layers of muscularispropria , the inner circular and the 
outer  longitudinal. These layers are striated in the upper 1/3rd and smooth 
muscle  in the lower 2/3rd . 
 
 
 The circular muscles are the extension of cricopharyngeus muscle. 
Transition of the circular muscle of the esophagus to the oblique muscle of  
the stomach is at the incisura is called as the ‘coller of Helvetius’ Between 
the muscular layers of the esophagus there are connective tissue ,blood 
vessels and the Auerbach’s plexus. Esophagus has no  serosal layer. It is 
wrapped by fibroalveolar adventitial  layer. 
Physiology of the esophagus .  
 The esophagus transports materials from the pharynx to the stomach, 
It restricts amount of air that swallowed and amount of the food material that 
is  regurgitated backward from the stomach. 
 In normal physiological conditions the esophagus allows easy 
effortless  unidirectional flow of the food materials towards the stomach. 
The upper esophageal sphincter is 4-5 cm long and has average resting 
pressure of 60 mm Hg , that prevents excess aerophagia.  
 The lower esophageal sphincter is 2-3 cm in length and has average 
resting  pressure of 6 to 26 mm Hg, that prevents excess regurgitation of 
food from  the stomach. Function of the lower esophageal sphincter is 
influenced by  various factors like gastric distension, alcohol consumption 
tobacco , and  hormonal variations. 
 Physiological events of deglutition in the esophageal phase. The food 
is propelled by the relaxation of the upper esophageal sphincter  and 
constriction of the posterior constrictor  .Upper esophageal sphincter  closes 
 
 
with pressure of 90 mm Hg, which prevents regurgitation of bolus to  the 
pharynx.  
 Post relaxation contraction of the upper esophageal sphincter  initiates 
primary peristalsis. The primary peristalsis moves in 2-4 cm/sec .Within 9  
secs the food bolus reaches the lower esophageal sphincter. The secondary 
peristalsis is progressive and initiated by the distension and  irritation of 
esophagus, to clear up material that left behind after the primary  peristalsis 
 
 The Tertiary peristalsis  is a non progressive one , that occurs 
following  voluntary swallowing or between swallows, that is uncoordinated 
and  esophageal spasm.  
 
 The lower esophageal sphincter is relaxed by vagal stimulation and 
that lasts for 3 to 6 sec that allows the  transport of the food bolus from the 
esophagus to the stomach. 
 Lower esophageal sphincter returns to the resting tone that prevents 
regurgitation. 
Etiology of Carcinoma of the esophagus 
 The tobacco consumption in any form ,including chewing, smoking 
and alcohol consumption are the main risk factors for carcinoma of 
esophagus, especially the squamous cell carcinoma all over the 
world,1,2 
 
 
 Dietary deficiencies of certain nutrients particularly the  vitamins 
A,C,E and deficiency of  minerals ,like zinc, selenium and 
molybdenum also play a major role in the development of carcinoma 
of esophagus1,2. 
 Consumption of spicy pickled ,smoked foods with increased contents 
of nitrosamine , habits of taking very hot beverages,  also play role in 
causing carcinoma esophagus ,commonly the squamous cell 
carcinoma. 
 Carcinoma also arises from the mucosal injury caused by caustic 
ingestion. 
 Plummer winson syndrome or Peterson Kelly syndrome characterized 
by the presence of esophageal webs, iron deficiency anemia, cheilitis 
and koilonychia is considered a risk for developing carcinoma 
esophagus1,2. 
 Tylosis – a familial syndrome characterized by increased thickening of 
palms and soles are associated with the increased risk of developing 
squamous cell carcinoma1,2. 
 GERD and obesity leads to decreased tone of LES that in turn cause 
acid reflux that causes chronic irritation of esophageal mucosa , which 
leads to metaplasia and dyplasia (Barret’s esophagus) which is a risk 
factor for developing adenocarcinoma1,2. 
 
 
 Presence of anatomical abnormalities like stricture, diverticula, and 
motility disorders including Achalasia also increases the risk of 
malignancy1,2. 
 The presence of other malignancies in the aerodigestive tract also 
increases the risk of malignancy in esophagus,2. 
 Several studies now suggest  that H .pylori infection particularly with 
the cag A strains are risk for developing adenocarcinoma , several 
studies conducted in South Africa also suggest that high prevalence of 
carcinoma  esophagus in some areas where  HPV infection plays role 
in the etiology,2. 
Clinical features of carcinoma esophagus: 
Clinical Presentation 
 Most malignancies of the esophagus  present with the cardinal 
symptom that is dysphagia or difficulty in swallowing its presence indicates 
that the disease is in the advanced stage, 50% of the esophageal lumen is 
usually occluded during the presentation of this symptom1,2,27,. 
 In the earlier stages the symptoms are often just mimic the GERD or 
Gastro esophageal reflux disease1,2,patient often complains of feeling of 
fullness, indigestion, early satiety, vomiting , nausea and burning sensation 
in the retrosertnal area. some times these  patients may present with 
breathing difficulty, or like asthma due to regurgitation of contents in to the 
respiratory tract.  
 
 
 Signs and symptoms of aspiration and severe dyspnea may also 
present if the disease is complicated with tracheoesophageal fistula 
formation1,2. 
 The patients also present with pain during swallowing or odynophagia, 
The main symptoms associated with difficulty in eating  and tumour related 
cachexia often lead to  loss of weight, the patients are often sick looking 
,emaciated with severe morbidity. 
 Carcinoma esophagus should be ruled out by doing endoscopy 
investigation while the  patients are evaluated for anemia that is  associated 
with or without dysphagia. In the advanced stages hoarseness of voice may 
present in case of recurrent laryngeal nerve is involved, and Horner’s 
syndrome in case of sympathetic trunk involvement,2. 
 Bone pain and paralysis of diaphragm are the signs if the disease well 
advanced. Involvement of the  supraclavicular nodes and skin changes are 
suggestive that the disease is a disseminated one .The disease is inoperable if 
these symptoms are already present,2. 
  Some patients with GERD and Barret’s esophagus are evaluated with 
endoscopy and  diagnosed during the surveillance procedures1,2. But these 
group of people are rare in the developing countries like India, In our 
country the people seek medical help only when they develop symptoms, 
and at that time they have already reached the advanced the stages and most  
of  them are inoperable at that moment unfortunatlely.  
 
 
Diagnosis and investigations1,2: 
 The carcinoma of esophagus is often diagnosed during the upper GI 
endoscopy procedure. 1,2 
By the upper GI endoscopy we can obtain the informations like  
 Site of the leision measured as distance from the incisor teeth. 
 Physical appearance of the tumour , like polypoidal, ulcerative, or 
ulcereoproliferative etc. 
 Extent of the tumour 
 Relationship with the cricopharngeal muscle, OG junction and 
stomach. 
 And the status of stomach is also studied. 
  The improved image resolution of modern endoscopes and novel 
techniques involving magnification and the use of dyesto enhance surface 
detail may lead to more early lesions beingrecognized. 
 If the suspected growth is seen during the endoscopy examination, 
tissue biopsy is taken and sent for Histopathologic examination, and the 
diagnosis is confirmed with type of the cancer and its grade.  
General assessment and staging 
 Squamous cell carcinoma usually affects the upper two-thirds; 
adenocarcinoma usually affects the lower third  
 The incidence of adenocarcinoma is increasing 
 
 
 Lymph node involvement is a bad prognostic factor 
 Dysphagia is the most common presenting symptom, but is a late 
feature1,2 
 Accurate pretreatment staging is essential in patients 
 The carcinoma of esophagus in the very early stage is usually without 
any symptoms, But by that time itself the malignancy tends to spread .The 
symptoms like difficulty in swallowing , excessive heartburns and pathologic 
significant loss of weight appear only when the tumour has become already 
advanced  , by that time only unfortunately it is often diagnosed .This 
character is common to the both of the histopathologic variants the 
adenocarcinoma and the squamous cell carcinoma.  
 The  spread of the  esophageal malignancy occur by direct invasion in 
to the adjacent organs and structures , This is facilitated by the absence of 
the serosal layer of esophagus, it can also spread through the lymphatic 
system, or through the blood , These are the important three ways through 
which the esophagus malignancy spread. 
 The esophagus is rich in the lymphatics which are present  within its 
wall itself known as the submucosallymphatics. This is one of the main 
differences with the other parts of GIT, where the lymphatic system is  in 
segmental pattern. That is why skip leisions are more common in the 
esophagus , and the spread through the lymphatic system can occur in all 
directions , but commonly in the caudal direction. The involvement of lymph 
 
 
nodes vary from the mediastinal to the celiac. The esophageal malignancy 
can spread through the blood to different organs ,more often to the  lungs, 
liver brain and the bones  . The transperitoneal spread is also possible if the 
location of tumour is in the abdominal esophagus. 
 
 When the patients are diagnosed with carcinoma ,they undergo 
detailed clinical examinations to asses their overall health status , including 
nutritional status comorbidities , so that the treatment for the particular 
patient can be planned. Fitness is very important to undergo surgical 
treatment like esophagectomy since the surgery related morbidity and 
mortality are high. Palliation for the purpose of  improving the quality of life 
of the patient  is planned for the patients with poor nutritional status , poor 
fitness, and with advanced disease . 
 Chemoradiotherapy may be planned for the patients with  squamous 
cell carcinoma after improving their nutritional status and quality of life by 
palliative procedures like SEMS placement, etc. 
 The patients with early disease and fit to undergo curative definitive 
procedures are evaluated further to diagnose the accurate staging of the 
disease. The are investigated for distant metastases and the local 
advancement is also assessed . 
 
 
 
 
 
Evaluation of local advancement: 
 The endoscopic ultrasound investigations with or without laparoscopy 
procedure is performed to assess the local advancement status of the disease. 
By this investigation T staging of the  leisions are diagnosed. The treatment 
is planned according to the TNM staging of the disease1,2. 
 For the T1 and T2 leisions definitive curativesurgical  procedure 
Esophagectomy isusully planned and for advanced lesions (T3/T4, N1) 
treatment is individually planned ,  
 
Table  TNM staging scheme for esophageal cancer 
 Tis is High-grade dysplasia 
 T1 If the Tumourextends to lamina propria or submucosa 
 T2 Tumour invades the layer muscularispropria 
 T3 Tumour invades  beyond  the layer muscularispropria 
 T4 Tumour invades all the layers then to adjacent structures 
 Tx IF the Primary tumour cannot be assessed 
 N0 IF there is no regional lymph node metastases 
 N1 If the  Regional lymph node metastases are present 
 Nx If the Lymph nodes cannot be assessed 
 M0  IF there is no distant metastases 
 M1(a) Coeliac node involved (for distal esophageal tumours) 
 Supraclavicular node involved (for proximal tumours) 
 
 
 M1(b) Coeliac or supraclavicular node involved if not remote from 
tumour site (i.e. not 1a) 
 Mx Distant metastases cannot be assesed 
 
 The  correct and accurate T staging and N staging are often can be 
done only after the esopgahectomy with lymphadenectomy and after the  
HPE of the  specimen is done. 
 
Some times  The patients described as N0 before surgery may become 
N1,after the HPE examination this is known as stage migration. 
 Staging information are done before the treatment is started,  during 
the treatment (e.g. at open surgery) or 
Following the  treatment (HPE or Autopsy).  
Blood tests 
 These are part of the routine investigation plan. Blood tests are not 
useful for the evaluation of  localinvasion , lymph node spread . 
 There are no specific tumour markers available to suggest the 
carcinoma esophagus. The  liver function tests abnormalities  may give some 
clues regarding the  liver metastases, but these are non specific.  
Transcutaneous ultrasound and Chest x ray: 
 It is These  investigations is nowadays performed as a routine the USG 
usually uses  low-frequency sound waves, thus the trans cutaneous 
ultrasound may diagnose the Haematogenous spread , asses the status of 
 
 
intra abdominal solid organs including liver, spleen, pancreas .The chest x-
ray may detect the lung metastases but with the computerized tomography 
these investigations are less accurate. 1,2 
 
Bronchoscopy 
 The carcinomas of the esophagus involving the  middle third- and 
upperthird of the esophagus are mostly  squamous cell carcinomas they are 
relatively fast growing and fast spreading tumours , they invade the adjacent 
structures including the trachea ,and  bronchi , in such conditions the 
bronchoscopy is useful in diagnosing the invasion of respiratory tract by the 
esophageal carcinoma. This may be useful for planning the further treatment 
strategies1,2.  
Laparoscopy 
 This is an invasive procedure usually  done under the general 
anesthesia , it diagnoses the peritoneal seeding , carcinomatosis ,liver 
metastases etc . Tissue biopsies are taken using the laparoscope. It is done if 
the carcinoma arises from the abdominal esophagus1,2. 
 
Computerised Tomography 
 It is an additional  diagnostic tool used for the more accurate 
diagnostic staging of carcinoma of esophagus .CT chest provides with 
detailed information about size and the extent of leision , thickness of 
esophagus. It also gives the information about the regional lymph node status 
 
 
and also it can diagnose the distant metastases to other organs , including 
liver, lungs etc. In the T4 leisions, it is useful in assessing the local invasion. 
Fistula and the anatomical variations can also be diagnosed and  is the 
modality most used to identify haematogenous metastases (Fig. 59.48). 
Distant organs are easily seen and metastases within them visualised with 
high accuracy (94–100%). The normal thoracic oesophagus is easily 
demonstrated by CT scanning. Nowadays with the use of spiral and thin slice 
CT  small size lymph nodes up to 5mm are also diagnosed more 
accurately.But it cannot differentiate whether the nodes are  metastatic or 
inflammatory1,2 . 
 
Magnetic Resonanceimaging : 
  Magnetic resonance imaging (MRI)  is not routinely done in the 
patients with carcinoma of esophagus, the advantage of MRI is it uses no 
ionizing radiation and iv contrast drugs also not needed. The thickness of the 
esophagus is assessed by the air that present in side lumen of the esophagus 
.The intra hepatic leisions and other soft tissues are very well assessed by the 
MRI , thus metastases are diagnosed more accurately1,2. 
Endoscopic ultrasound 
  It is an one more diagnostic tool used to assess the staging of 
carcinoma of esophagus, the length and depth of the tumour can be assessed 
by the EUS .These are very important in staging the disease , because it 
 
 
gives the information about how deep the tumour is penetrated in to the 
esophagus wall and to the adjacent anatomical structures. This information is 
useful for assessing the prognosis factors . The advantage of Endocopic 
ultrasound over the CT scan that has limited axial resolution is the ability of 
EUS in assessing the depth ,invasion and the involvement of the regional 
lymph nodes. The T 1 stage and T3 stage and the T4 staging are very well 
diagnosed by the EUS , that cannot be done with the cutaneous ultrasound. 
Narrow EUS instruments are available for insertion over a guidewire to 
minimize the risk of technical failure, and linear array echo endoscopes can 
be used to biopsy lesions that might signify incurability outside the wall of 
the gastrointestinal tract1,2 
(e.g. coeliac lymph nodes).. 
 When used in isolation, there are problems with the anatomical 
location of these areas. This has been significantly improved by combining 
PET with CT . Although there are wide variations between centres, a change 
in stage is frequently reported in around 15% of patients. It has also been 
suggested that a reduction in PET activity following chemotherapy might be 
a way of predicting ‘responders’ to this approach. . 
Positron Emission Tomography/computerised tomography 
scanning1,2 
  (PET)  is an another diagnostic modality it can detect the tumour by 
the high metabolic activities that occur in the tumour cells. 
 
 
 This is done by the administration of radiopharmaceutical drug known 
as 18 F- fluorodeoxyglucose to the patients. After entering in to the tumour 
cells it got phosphorylated , the phosphorylated FDG 6 phosphate gets 
accumulated in the cells where the metabolic activity is very high,  since it is 
not metabolized further. The carcinoma of esophagus are also metabolically 
very active and easily visualized by the PET scan this is achieved better by 
its combination with the CT , rather that using it isolated accumulates in 
metabolically active cells. Primary esophageal cancers are usually 
sufficiently active to be easily visible, and spatial resolution of positive PET 
areas occurs down to about 5–8 mm. When used in isolation, there are 
problems with the anatomical location of these areas. This has been 
significantly improved by combining PET with CT  1,2. 
 
Treatment of Carcinoma esophagus: 
Treatment choices of carcinoma of the oesophagus2 
 Radical oesophagectomy is the most important aspect of curative 
treatment 
 Neoadjuvant treatments before surgery may improve survival in a 
proportion of patients 
 Chemoradiotherapy alone may cure selected patients, particularly 
those with squamous cell cancers 
 
 
 Useful palliation may be achieved by chemo/radiotherapy or 
endoscopic treatments. 1,2 
Principles for treatment: 
 For the early cancers with T1- T2 staging esophagectomy with 
lymphnode dissection gives better cure rates , but the procedure should be 
done precisely to avoid the staging error and to decrease the local recurrence 
rate,2 . 
 Studies, that were  conducted in Japan suggest that esophagectomy 
done with curative intent and with adequate lymphnode dissection improves 
the survival rate. The curative esophagectomy procedure should give 
importance to adequate margin clearance of  10 cm above the cancer 
macroscopically  and 5 cm to the cancer distally. Local recurrence are more 
common if such adequate margin clearance is not possible squamous cell 
carcinoma, is esophagectomy is often followed by  postoperative 
radiotherapy avoids the  local recurrence, but in such cases the survival is not 
improved. 
 Adenocarcinoma commonly involves the lower third of esophagus and 
tend to metastasize to liver often, it may also involve the  cardia, and fundus 
of stomach, so during esophagectomy for such patients the portion of the 
stomach is also excised for the purpose of achieving margin clearance and 
lymphnode1,2dissection,may therefore extend into the fundus or down the 
lesser curve 
 
 
 Most of the patients with carcinoma esophagus when diagnosed, present 
with inoperable disease .This inoperability rate accounts for about 60% to 70 
% . 
 The main aim of treatment in such patients is the palliation. The 
palliative treatment procedures are aimed to relieve or improve the 
dysphagia , which is one of the most distressing symptoms of carcinoma of 
esophagus and its relief  that is restoration of swallowing function is needed 
to improve the quality of life of the patients.  
 The patients with advanced carcinoma of esophagus usually have low 
survival rate , and the palliative procedure that suits particular individual 
patient is planned according to his need. The tumour site its morphology , 
fitness of the patient, nutrition status of the patient are considered before 
planning a palliative procedure.  
 In carcinoma esophagus even T2 leisions can spread to the local 
lymph nodes , because of the submucosal lymphatics present in the 
esophagus. 
 The Barret’s esophagus with high grade dysplasia often becomes 
malignant, so  if it is diagnosed , and the fitness of  the patients are also good 
then esophagectomy is the best suited procedure.  
Surgical Treatment procedures with curative intent: 
 The Surgical procedure done for the carcinoma of esophagus is  
Esophagectomy,2.Mostly this procedure is planned for  the fit  patients with 
 
 
T1 , T2 disease ,and have  nonodal spread  (N0). The preoperative 
investigations are very well planned to  accurately stage the disease, 
Esophagectomy alone done and adequate for the patients  with the staging 
T1 NO Mo  . The cure rate achieved in  those patients is around 55% to 75 %  
 
 Multi modal treatment is planned for the patients who have advanced  
disease staging .Such patients are treated with Neoadjuvant chemo radiation 
therapy or post operative adjuvant chemo radiation1,2. 
 It is important that esophagectomy should be performed with a low 
hospital   mortality   and    complication   rate. Case  selection,  volume and 
experience of the surgical team are all equally  important. 
 Preoperative risk analysis has shown that this can play a major 
part in reducing hospital mortality.  The following  Surgical procedures are 
done for tumours in the mid and distal esophagus 
Transthoracic surgical procedures : 
1)    Ivor Lewis operation 2 
 Right thoracotomy is combined with the  laparotomy 
2) McKeownoperation2 
 Right thoracotomy is done combined with  laparotomy, and 
cervical approach and   anastomosis is done. 
3) Left thoracotomy2 
4)   Left thoracoabdominal 
 
 
 
 The type of the cancer its site the extent of lymphnode dissection are 
important factors that influence the prognostic outcome of the disease. 
 The left thoraco abdominal approach is very difficult to perform due 
to the aortic arch which is situated proximally, therefore the surgery is often 
not feasible if the tumour is in the upper esophagus..  
 
Non surgical Treatment Procedures: 
    1)Photo DynamicTherapy (PDT) 2 
 The photodynamic treatment is  an treatment modality, often planned 
for the patients who are not fit for surgery .  This is an endoscopic procedure, 
a photosensitiser is administered to the patients and it is  taken up by the 
tumour cells . Then the tumour is exposed to the laser light .  The tumour 
ablation is done in such way has so many adverse effects too, including  skin 
photo sensitisation, stricture formation.etc. 
Non-surgical treatment methods:  
 Radiotherapy was the only treatment modality that  was  used until 
1970.It was mostly used for the treatment of squamous cell carcinoma .The 
five year survival was very low and less than 6% for the patients who were 
treated with radiotherapy alone. So studies were focused on the multimodal 
treatment procedures, and multimodal treatment was given to patients later 
in the  1980s,combined with chemotherapy the survival rate of squamous 
cell carcinoma was on par with the esophagectomy surgery. But the 
 
 
treatment is not a curative one, the local recurrent rates were very high, so 
the treatment with surgical procedures gained importance. 
 The chemo-radiation treatment was often reserved for surgically unfit 
patients, Theesophagectomy surgery had high mortality and post operative 
morbidity, The patients often developed postoperative respiratory distress, 
anastomosis leak. 
 Due to long post operative period and high morbidity, the patients 
were often depressed and needed psychiatric counseling.  
 So it was difficult to come for the final opinion regarding better 
treatment option in patients with carcinoma esophagus. 
 The low survival rate of the disease and morbidity , forced the treating 
physicians to look for better palliative procedures with less morbidity but at 
the same time improved the quality of life of patients. 
 For the palliation of disease Surgical treatment  and the external beam 
radiotherapy were combinely done, and tried but it didn’t improve the 
survival rate too. So all these surgical procedure were extra burden for the 
patients with short remaining life span. so the surgical treatments including  
bypass procedures were rarely done and  simple palliative procedures were 
explored. So that the cardinal symptom dysphagia is relieved and , the 
patients can  live their remaining life with improved quality of life. 
Endoscpic palliation techniques: 
The main aim of the palliation is dysphagia relief. 
 
 
Endoscopic laser treatment: 
 This procedure was  done by inserting a channel in to the growth  and 
the tumour was destructed by heat produced by the LASER .The dysphagia 
improvement was better but the procedure is not simple ,It should be 
repeated for several weeks. so the use of LASER is now restricted to unblock 
the stent occlusion caused by the tumour over growth 2. 
Esophageal stenting: 
 For the palliation of dysphagia, varieties of stents were tried , 
including the tubes of coiled silver wire  known as the Souttar tube, rigid 
plastic tubes were tried for implantation . these procedures were done as 
endoscopic procedures.Later lot of research were done on stent palliation, 
thus the SEMS or self expanding metallic stents were developed which were 
easy to insert, with a little morbidity ,  avoided the general anesthesia 
,surgically unfit and nutritionally poor patients were benefited , with 
improved dysphagia relief thus their health related quality of life also 
improved. The SEMS are initially in the collapsed state  before the insertion, 
and it expands automatically after the insertion in side the lumen and it 
increased the width of the lumen very well ,thus improved dysphagia. 2 
Different types of Stents: 
There are different types of esophageal stents available now10,21 ,like  
 Plastic Stents 
 Metallic Stents or SEMS 
 
 
 Fully covered SEMS, 
 partially covered SEMS,  
 uncovered SEMS,  
Fig 7.Types of Esophageal Stents. 
 
  The covered SEMS were useful in the setting of trachea esophageal 
fistula, the Meshed SEMS prevent the stent displacement . Placement of 
stents over the tumours that are more  proximally located ,including the 
tumours  near the cricopharyngeus, is poorly  tolerated by the patients. The, 
stents placed over the  the gastroesophageal junction are associated with 
complications including  migration of the stents to the stomach they are also 
associated with the acid regurgitation.  
Indications for stenting : 
 Grade 3 or grade 4 dysphagia in any stage of carcinoma   esophagus  
 Dysphagia due to mucositis and stricture following radiotherapy ,or 
chemotherapy in carcinoma esophagus. 
 Inoperable ,locally advanced or advanced carcinoma esophagus with cancer 
cachexia or nutritional deficiency, with severe dysphagia. 
 
 
Esophageal dilation  
 It is a very simple procedure that can be useful in relieving dysphagia  
immediately but , the dilatation  effect is only temporary which lasts for less 
than 30 days. Repeated  dilations are often needed to maintain the effect,  
and the procedure is with its own complications too, including 
perforation.etc.  due to its limitations the dilatation procedure  is limited, and 
is mostly performed before the SEMS insertion procedure. 
Other endoscopic methods: 
 The other palliative endoscopic procedures include  bipolar diathermy, 
argon-beam plasma coagulation and injection of sclerosing agents like 
alcohol 
 
 Brachytherapy is another palliative treatment modality it is done by  
delivering radiation directly in the lumen or over the growth13,2this is an 
expensive treatment modality . These methods are indicated for the patients 
with advanced carcinoma, 
 
 Among these palliative procedures the SEMS placement found to be 
simple cost effective and has less complications. 
Self Expanding Metallic stent placement procedure: 
 SEMS or Self expandable metallic stents are devices, when placed 
across the narrowed or  occluded lumen of esophagus they expand in width 
and keep the esophagus  dilated, thus making way for easy passage of food 
 
 
and water, SEMS  are easy to insert and done as a day care procedure with 
minimum requirement of anesthesia, and it is well tolerated procedure, has 
less morbidity. 
 Placement of stents with meshed stents SEMS, the stents with metallic 
non injuring blunt barbed stents can decrease the incidence of migration of  
stent , and  the use of stents which are coated with silicone or polyurethane  
prevent or delay tumor in growth and subsequent esophageal obstruction. 
Fig. 8. SEMS and Delivery system. 
 
 
 
 
 
 Usually the SEMS placement is done by General Surgeons or Medical 
or Surgical Gastroenterologists in India. The SEMS  can be  placed as an out 
patient procedure but  the patients are usually admitted  prior to the 
procedure Placement of stents with metal mesh and barbs  can reduce the 
migration of stent , The stents are now coated with  silicone  and 
polyurethane that can prevent and may be they  delay tumor in growth and 
occlusion of esophagus is prevented. 
 
Steps to prepare for the SEMS placement procedure: 
 The patients are kept Nil By Mouth for 6 hours prior to the procedure, 
patients can drink water up to 2 hours before the procedure  
 Patients are asked whether they are allergic to any medications or they 
have bronchial asthma   
 Patients  can take all their drugs  as usual, except anticoagulants , like 
warfarin, Aspirin etc and they are advised to stop taking it before 5 
days . 
The procedure is explained in detail regarding its benefits ,complications  to 
the patients and the written consent is obtained. 
 After getting the consent the patient is examined and the vitals are 
checked, local anesthetic spray is applied to the throat, and iv sedation is 
given if necessary. 
The equipment contains  
 
 
 Upper GI endoscope,  
 Guide wire ,  
 Catheter with self expanding metallic stent. 
 First the endoscope is passed the narrowing are is visualized then the 
guide wire is passed beyond the narrowing caused by the tumour, then the 
catheter with SEMS is introduced then passed  into the correct position 
across the blockage, after confirming the correct position catheter is released 
and removed after the SEMS is placed precisely in the correct location. 
 After self expanding esophageal  stent placement, the  people have an 
improvement in dysphagia. 
As with any medical treatment, there may be  some  complications that can 
arise: 
Minor complications: 
• Slight bleeding may occur during the procedure, but this usually  
stops without any specific intervention . 
• Mild or moderate pain while the stent ‘beds in’, that also usually 
settles within  24 hours to 72 hours 
• Some patients get acid reflux afterwards and need antacid therapy 
for this. 
• Rarely the stent may slip out of position. if it happens, patient may 
have to undergo repeat of the procedure. 
 
 
 
Major complications 
 Uncontrolled bleeding and 
 Esophageal perforation occurs rarely 
Food intake after esophageal stenting : 
 The  will be able to start on fluids within a few hours. Patients are 
advised to have  liquid diet for one or two days, after confirming the correct 
placement of the stent by X ray then soft solid diet is started 
 The stent is  placed to relieve the dysphagia and allow the patient as 
normally as possible. But  the physician should advise the patient not to 
forget the possibility of the stent getting blocked. The stents may get blocked 
if the food is not sufficiently chewed and  swallowed or  from the hard food 
particles that are difficult to break when chewed. 
 The following foods are  difficult to break down, despite chewing, and 
may cause the stent to get blocked Fish bones, Tough gristly meat  Hard 
boiled or fried egg , fruits like orange, pineapple, Raw vegetables and 
Stringy vegetables like , greens potato skins, salad leaves etc 
 To prevent the stent blocking the patients should take more  time, 
relax and eat meals slowly.¬ Meals should be smaller   than the patients are 
used to and patients should have more frequent food intake like  five or six 
small meals rather than three big meals. 
 
 
  Cut the  food into smaller pieces before eating normally  take smaller 
mouthfuls and chew each mouthful very well.  spit out the lumps that cannot  
be chewed well. 
  Take plenty of , gravy or cream ,curry with less spices and mix it with 
the  meals. It makes the  food moist, and become easier to swallow and pass 
through the stent. 
   Drink water frequently during and after meal it will  help to  keep the 
stent clear. Warm or carbonated drinks can be consumed and note that  all 
fluids are beneficial. If the carbonated drinks  worsen symptoms of heartburn 
or acid reflux. Sit upright at meal times and for one to two hours  afterwards. 
 If  the patients wear dentures, make sure to them  fit correctly, so that 
food can be chewed well. Take the drugs in liquid form if possible or take 
them with plenty of fluids. 
 If the patients  have  poor appetite or they are losing weight, they will 
be advised to  Eat small amounts but frequently, Choose full cream milk and 
full fat foods instead of low fat products if it is not contraindicated 
otherwise. Add sugar to cereals, puddings and beverages if the patients are 
non diabetic 
 
 If the patients  are unable to maintain their weight, a dietitian advice 
may be sort or recommend some high calorie nutritious recipes or Potential 
problems associated  stent 
 
 
 If the stent needs to be placed across the esophago gastric junction. An 
antacid therapy is needed, and  the sleeping posture should not be too flat. 
 Prop up position   up to a 30-450 angle will be useful .it can be done 
by using pillows or a bed spread. When the stent  expands it can cause 
compression that leads to some pain , usually the pain  subsides after 72 
hours. Proper are used to control the pain. 
 The patients are advised to get reviewed   If the dysphagia still persists 
despite the stent placement  , because it may be due to the incorrect position 
of the stent or due to the stent migration,and the patients may need stent 
replacement. 
Self Expanding Metallic stent placement procedure: 
Fig .9  Obstruction due to carcinoma 
 
 
 
Fig  10.Guidewire passed through the tumour stricture 
 
 
Fig  11Stent delivery system passed through the tumour stricture 
 
 
 
Fig12  Stent placement done 
 
 
Fig 13.correction of position 
 
 
 
 
 
 
 
 
 
 
 
Fig 14.Final position after stent deployment. 
 
Fig 15.Stent after 0ne week and after 8 weeks. 
          
 
 
 
 
 
Research and studies: 
 In our extensive search, we  found that there are only limited studies 
were done evaluating the  improvement of quality of life after esophageal 
stenting in patients with carcinoma esophagus  ,most of the  studies 
calculated the relief of dysphagia as the only indicator for the improvement 
of quality of life. The disease also has physical, emotional and social impacts 
on the life of patients, these parameters were not adequately considered. 
Most of the studies focused only on relief of dysphagia ,and survival benefit 
of esophageal stenting, where as few studies compared the other palliative 
 procedures with the esophageal stenting. Eg single dose radiation 
brachy therapy palliative treatment was compared with esophageal stenting, 
Some studies compared other  palliative procedures ,including PDT  and  
cautery with the esophageal stenting. 
 Few studies focused on assessing improvement of  quality considering 
the physical, emotional and social impacts on the life of patients , other 
anthropometrical, biochemical improvements were not adequately  studied. 
In our study we tried to evaluate the health related improvement of quality of 
life (HRQOL) along with the improvement of anthropometrical, and 
biochemical improvement after stenting.  
 
 
 
 
 
MATERIALS AND METHODS 
 The patients above 18 years of age with carcinoma of esophagus  
posted for esophageal stenting as per indications, who were  willing to 
participate in the study after giving written informed consent, were studied 
over the period of one year between June 2014 to June 2015. 
Study design: 
This study is a prospective  study. 
Place of Study 
 The  study was conducted in the department of General surgery and in 
the department of Gastroenterology, Govt Coimbatore Medical College 
Hospital, Coimbatore, after obtaining permission from The Heads of  the 
concerned departments. 
Sample size calculation: 
The sample size required for this study was estimated with an assumption of 
statistical significance at 95% and power of study at 80% using the following 
formula: 
  n =   2 x {zα + zβ} 2 x {SD}2  /  {Mcase -  Mctrl}2 
where 
n = estimated sample size 
zα = 1.96 ( at statistical significance of 95%) 
zβ = 0.84 ( for a power of study at 80%) 
SD = 10.3 Standard deviation12 (reference no 12) 
 
 
{Mcase-  Mctrl} =  39effect size12 (reference no 12) 
M case =112  
Mctrl  =  73 
Based on above calculation, the estimated sample size required for this study 
was around 2  cases12 . 
 A total of 21 patients with a diagnosis of Carcinoma esophagus with 
grade 3 and grade 4 dysphagia who were posted and deployed covered Self 
expanding metallic stents were studied .  
SELECTION CRITERIA  
(a) Inclusion Criteria  
 The patients above 18 years of age with carcinoma of esophagus  
posted for esophageal stenting as per indications, who are willing to 
participate in the study after giving written informed consent. 
  
(b) Exclusion Criteria  
 Pregnant women 
 Persons not capable of giving consent (psychiatric patients) 
 Persons unwilling to undergo the study (who refused to consent) 
Statistical Tools: 
 The information and results collected from all the selected subjects 
were recorded in the Master Chart. Data analysis was done with the help of 
spss software version 19.5. 
 
 
   Using this software Paired t test , range, means, Standard deviations , 
and p values were calculated. A ‘p’ value less than 0.05 is taken to indicate 
the statistically significant relationship. 
Ethical Clearance: 
 The study was conducted after getting prior permission from the 
department of Gastroenterology and General Surgery and the study proposal 
was approved in the  ethics committee meeting conducted at Government 
Coimbatore Medical College, Coimbatore. 
 An  informed consent was obtained from the subjects, both male and 
female patients  with carcinoma of esophagus with  dysphagia admitted  in  
the  IP departments of the Coimbatore Medical College Hospital, 
Coimbatore, Posted for the SEMS(self expanding metallic stents),placement, 
during the period of study (i.e. July 2014 to June 2015). 
 The type of stent used was  covered self expandable metallic  meshed 
stent, the same type was used for all the patients.  
Pre-intervention assessment: 
 All subjects included in the study had undergone the following 
investigations and questionnaire based interview:  
1. Quality of life was assessed with EORTC c30 OES 18 questionnaire 
2. completehemogram,  
3. absolute and differential blood cell counts,  
4. Renal function test,  
 
 
5. liver function test,  
6. serum lipid profile, 
7. blood sugar   
 The research includes interview of study subjects to collect data on 
socio demographic, disease and treatment related variables. The subjects 
were also underwent a detailed clinical examination. A questionnaire based 
enquiry of quality of life and psychomorbidity which was  administered to 
all the subjects before the  esophageal stenting  which is a part of standard 
treatment protocol and 
Post intervention assessment  
 All subjects were  evaluated for improvement of quality of life with 
the EORTC C 30 OES 18 questionnaire,  after the placement covered SEMS 
at the end of 1 week 4 weeks and 8 weeks after stenting respectively. 
 All subjects were  evaluated with following standard laboratory tests 
at the end  and 4 weeks and 8 weeks after placement of SEMS respectively. 
1. completehemogram,  
2. absolute and differential blood cell counts,  
3. Renal function test,  
4. liver function test,  
5. serum lipid profile, 
6. blood sugar   
 
 
 
Methods  
  First  the informed consent was obtained from the subjects to undergo 
the study, then the details were collected , including medical history and 
clinical examination of the subject, above mentioned lab investigations were 
done,   
Assessment of Health related Quality of Life (HRQOL) 
 The health related quality of life was assessed with the questions 
based on translated Tamil version of EORTC QLQ –C30 . 
  The EORTC QLQ- OES 18 is a set of questionnaire developed by the 
European Organization for Research and Treatment of Cancer, to assess the 
quality of life of cancer patients. The questionnaire consists of total 18 
questions first 4 four questions represent the dysphagia score .The response 
options each of the question are on a 4 point scale where 1  indicates 
maximum dysphagia and 4 indicates no dysphagia. 
 
The questions are based on the following responses 
1. Is the patient able to  eat solid food? 1 2 3 4 
2.  Are the patients able to eat semi solid or soft food? 1 2 3 4 
3.  Are the patients able to  you drink liquids? 1 2 3 4 
4.  Whether the patients able to swallow saliva?1 2 3 4  
 1 point for response Not at all , 2 points for A little ,3 points for Quite 
a bit, and  4 points given for, if the response to the question is Very much. 
 
 
 
 Questions from 7 to 15   represent the general health and social 
activities related quality of life, 4 points given to the response for each 
question indicates maximum impairment in quality of life, and the 1 point 
indicates no impairment. 
7. whether patients had  trouble with eating? 1 2 3 4 
8.  whether patients had  trouble with eating in front of other people? 1 2 3 4 
9.  whether patients had  a dry mouth? 1 2 3 4 
10.  whether patients had  problems with your sense of taste? 1 2 3 4 
11. whether patients had  trouble with coughing? 1 2 3 4 
12.  whether patients had  trouble with talking? 1 2 3 4 
13.  whether patients had  acid indigestion or heartburn? 1 2 3 4 
14.  whether patients had  trouble with acid or bile coming into their mouth? 
 
 The question items from 16 to 18 indicate the pain related quality of 
life the  , 4 points were given for maximum pain perception response and 1 
point for no pain perception. Thus the quality of life was measured in three 
categories.  
15. whether patients had  pain when they eat?  
16.  whether patients had  pain in their chest?  
17.  whether patients had  pain in their stomach? 
 The question items 5 and 6 were omitted due to ambiguity in points 
calculation .and not considered for calculation . 
 
 
 
 The subjects were evaluated by the above described methods before 
and at the end of the 1, 4and 8 weeks after stenting respectively . The results 
were analysed by paired t test and the p value was calculated with spss, 19.5 
version software  
SOURCE OF DATA 
Data consists of primary data, collected by the principal investigator directly 
from the patients, who had approached the Government Medical College 
Hospital, Coimbatore and patients admitted as a inpatients in department of 
General Surgery, and Medical Gastroenterology. 
  
 
 
RESULTS 
 General characteristics of study population. 
Table 1:General characteristics of study population 
Variables 
 
N = 21 
Age (in Years) 
 
51.19 ± 8.37 
Gender (male) 
 
12 (57.1%) 
BMI (Kgs/m2) 
 
20.63 +2.27 
Tobacco smoking 
 
12 (57.1%) 
Tobacco chewing 
 
8 (38.1%) 
Alcohol intake 
 
11 (52.4%) 
Histopathological type 
Adenocarcinoma 
Squamous cell carcinoma 
 
10 (47.6%) 
11 (52.4%) 
Location of tumour 
Mid third of esophagus 
Lower third of esophagus 
 
11 (52.4%) 
10 (47.6%) 
Stage of cancer 
Stage III 
Stage IV 
 
17 (81.0%) 
4 (19.0%) 
Dysphagia Grade Grade3 
                                      Grade4 
16(76.2%) 
5(23.8%) 
 
 
  
 
 
Total  21subjects were studied. 
 There were  12 males (57.1%) and 19 females (42.9%). 
 The Age of the patients ranged from   45 years to 73  years with a 
mean + SD of    51.19+ 8.37. 
 Sixteen patients were with 
 The BMI of the patients ranged from   to  with a mean +SD of 
20.63+2.27.  
 The number of  patients who  smoked  tobacco were 12 (57%) and 
chewed tobacco were 8(38.1%) . 
 Alcohol consumption was noted in 11 patients (52.4%)  
 The histopathologictype, the total number of adenocarcinoma were 
10(47.6%), and the number of squamous cell carcinoma were  11 
(52.4%). 
 In 11(52.4%) patients the tumour was located in the middle third and 
1047.6%) patients had tumour in the lower third of esophagus 
 The number of patients with Stage 3 disease with severe dysphagia 
were 17 (81%) and stage 4 disease were 4(19%) . 
 Four Patients (19%) were with comorbid condition diabetes mellitus 
and  patient were with Hypertension . 
 Twenty patients(95.2%)were from urban area ,and only one patient 
(4.76%) was from rural area . 
 There was stent migration observed  in one patient (4.76%) 4 days 
after stenting for which reinsertion was done. 
 
 
 
 
 
 
Table 2 , The symptom burden and global health of subjects before and 
after stenting. 
variables Before 
stenting 
One week 
after stenting 
Comparison 
Four weeks 
after 
stenting 
Eight weeks 
after 
stenting 
Dysphagia 
score 
6.10 + 1.48 12.57 + 2.29 15.05 + 1.74 15.57 +1.74 
Pain Score 
 
7.10 + 1.54 10.00+1.97 5.38+1.53 4.00+0.95 
Global health 
score 
32.45 + 2.24 26.33+3.56 15.05+2.22 13.14+1.98 
  
  
 
 
 
 
Chart 1: Comparison of dysphagia score before and after stenting for 
esophageal cancer. The bars represent the mean score of Dysphagia and 
the error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of dysphagia. 
 
 
 
The improvement of dysphagia to solids and liquids improved significantly 
after stenting (p<0.0001) 
  
 
 
 
 
 
 
 
Table3: Comparison of dysphagia score before and after stenting using 
paired t test. 
Timelines in 
relation to stenting 
Mean + SD Mean difference + SD 
(compared with score 
before stenting) 
P value 
Before stenting 
 
6.10 ± 1.48 -  
One week after 
stenting 
12.57 ± 2.29 6.47 ± 2.44 < 0.0001 
Four week after 
stenting 
15.05 ± 1.74 8.95 ± 2.57 < 0.0001 
Eight weeks after 
stenting 
15.57 ± 1.20 9.47±1.83 < 0.0001 
 
The improvement of dysphagia to solids and liquids improved significantly 
after stenting (p<0.0001) 
  
 
 
 
 
 
Chart 2.Comparison of personal health related quality of life score 
before and after stenting for esophageal cancer. The bars represent the 
mean score of personal health related quality of life and the error bar 
indicates standard deviation. P value gives statistical significance of 
association of ‘after stenting’ scores with ‘before stenting’ scores of 
personal health related quality of life . 
 
 
The Improvement in personal health related Quality of life after stenting is 
statistically significant.(P<0.0001) 
 
 
 
 
 
Table 4: Comparison of Personal health related QOL score before and 
after stenting using paired t test 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference + SD 
(compared with score 
before stenting) 
P value 
Before stenting 
 
32.95+2.24 -  
One week after 
stenting 
26.33±3.56 6.61±3.98 P<0.0001 
Four weeks after 
stenting 
15.05±2.22 17.90±2.98 P<0.0001 
Eight weeks after 
stenting 
13.14±1.98 19.81±2.37 P<0.0001 
 
The Improvement in personal health related Quality of life after stenting is 
statistically significant.(P<0.0001) 
 
 
 
 
 
 
 
Chart 3: Comparison of pain score before and after stenting for 
esophageal cancer. The bars represent the mean score of Pain and the 
error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of Pain related quality of life. 
 
 
The Pain increases  up to one week significantly(p<0.0001) after stenting 
and then it decreases significantly at 4th and 8th weeks,(P<0.002) 
and(P<0.0001) respectively. 
  
 
 
 
 
 
 
 
Table 5: Comparison of pain score before and after stenting using 
paired t test. 
 
Timelines in 
relation to stenting 
Mean + SD Mean difference + SD 
(compared with score 
before stenting) 
P value 
Before stenting 
 
7.10±1.54 - - 
One week after 
stenting 
10.00±1.97 2.290±2.42 P<0.0001 
Four week after 
stenting 
5.38±1.53 1.714±2.26 P<0.002 
Eight weeks after 
stenting 
4.00±0.95 3.09±1.64 P<0.0001 
 
 
 The Pain increases  up to one week significantly(p<0.0001) after 
stenting and then it decreases significantly at 4th and 8th weeks,(P<0.002) 
and(P<0.0001) respectively. 
  
 
 
 
 
Table 6.,Comparison of anthropometric and biochemical variables in 
subjects before and after stenting. 
variables Before stenting Four week after 
stenting 
Eight weeks 
after stenting 
BMI (kgs / height m2) 
 
20.63±2.28 20.73±2.16 20.99±2.10 
Hemoglobin g/dl 
 
10.53±1.48 10.54±1.35 10.95±1.37 
Blood sugar mg/dl 
 
125.67±63.24 114.1±42.4 119±25.38 
Blood urea mg/dl 
 
37.86±9.45 37.14±7.76 32.86±6.14 
Serum Creatinine 
mg/dl 
1.074±0.28 1.019±0.28 0.995±0.20 
Total proteins g/dl 
 
5.92±0.78 6.25±0.67 6.47±0.58 
Serum albumin g/dl 3.63±0.5 3.89±0.32 4.06±0.43 
Serum globulin g/dl 2.28±0.49 2.35±0.43 2.41±0.59 
Total bilirubin mg/dl 
 
0.86±0.19 0.93±O.21 1.65±2.28 
SGOT , 
IU/L 
36.29±6.2 33.24+4.9 39.52+4.79 
SGPT , 
IU/L 
33.33±6.32 36.90+12.31 44.81+6.78 
 
 
 
 
 
Chart 4 :    Comparison of BMI score before and after stenting for 
esophageal cancer. The bars represent the mean score of BMI and the 
error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of BMI. 
 
The improvement of BMI is non significant 4 weeks after stenting, but it is 
statistically significant after 8 weeks.(p=0.308) and (p<0.001) respectively. 
 
  
 
 
 
 
 
 
 
Table, 7  Comparison of   BMI before and after stenting 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference 
+ SD 
P value 
Before stenting 
BMI 
20.63+2.28 - - 
BMI 4 weeks 
after stenting 
20.73+2.16 0.09+0.38 0.0281 
BMI 8 weeks 
after stenting 
20.99+2.10 
 
0.36+0.6 0.072 
 
The improvement of BMI is non significant 4 weeks after stenting, but it is 
statistically significant after 8 weeks.(p=0.308) and (p<0.001) respectively  
 
 
Chart  5: .Comparison of Hemoglobin score before and after stenting 
for esophageal cancer. The bars represent the mean score of 
Hemoglobin and the error bar indicates standard deviation. P value 
gives statistical significance of association of ‘after stenting’ scores with 
‘before stenting’ scores of Hemoglobin.
 
 The improvement of Hemoglobin level is non significant 4 weeks after 
stenting but it is statistically significant 8 weeks after stenting.(p=1) and 
(p=0.023) respectively. 
 
 
 
 
 
 
 
 
 
Table 8       Comparison of   Hemoglobin before and after stenting 
 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
Hb 
 
10.53+1.48 - - 
4 weeks after 
stenting Hb 
 
10.53+1.35 0.00+0.58 1.00 
 
8weeks after 
stenting Hb 
10.95+1.37 0.41+o.77 0.023 
 
 The improvement of Hemoglobin level is non significant 4 weeks after 
stenting but it is statistically significant 8 weeks after stenting.(p=1) and 
(p=0.023) respectively. 
  
 
 
Chart 6 : Comparison of Total protein score before and after stenting 
for esophageal cancer. The bars represent the mean score of Total 
proteins and the error bar indicates standard deviation. P value gives 
statistical significance of association of ‘after stenting’ scores with 
‘before stenting’ scores of Total proteins. 
 
 The improvement of Total proteins is statistically significant after 4 
weeks and 8 after stenting.(p=0.032) and (p=0.011) respectively. 
 
 
 
 
 
 
 
 
 
 
Table 9.Comparison of Total protein score before and after stenting for 
esophageal cancer. 
Timelines in 
relation to stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
5.92+0.78 - - 
After 4 weeks 
 
6.26+0.67 0.32+0.72 0.051 
After 8 weeks 
 
6.47+0.58 0.553+0.88 0.01 
 
 The improvement of Total proteins is statistically significant after 4 
weeks and 8 after stenting.(p=0.032) and (p=0.011) respectively. 
  
 
 
Chart 7 :  Comparison of Albumin score before and after stenting for 
esophageal cancer. The bars represent the mean score of Albumin and 
the error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of Albumin.
 
 The improvement of Albumin level is statistically significant after 4 
weeks and 8 weeks after stenting. 
  
 
 
 
 
 
 
 
Table,10:    Comparison of   Albumin before and after stenting 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
3.63+0.57 - - 
After 4 
weeks 
 
3.89+0.32 0.25+0.51 0.32 
After 8 weeks 
 
4.06+0.43 0.43+0.69 0.011 
 
The improvement of Albumin level is statistically significant after 4 weeks 
and 8 weeks after stenting. 
  
 
 
 
 
 
 
Chart 8: Comparison of Globulin score before and after stenting for 
esophageal cancer. The bars represent the mean score of Globulin and 
the error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of Globulin.
 
 The improvement of globulin level is non significant statistically after 
4 weeks but the improvement is significant 8 weeks after stenting.  
 
  
 
 
 
 
 
 
Table,11:Comparison of  Globulin before and after stenting 
Timelines in 
relation to stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
2.28+0.49 - - 
After 4 weeks 
 
2.35+0.43 0.071+0.58 0.581 
After 8 weeks 
 
2.41+0.59 0.127 0.77 
 
The improvement of globulin level is non significant statistically after 4 
weeks but the improvement is significant 8 weeks after stenting.  
  
 
 
 
 
 
Chart 9 : Comparison of Total Bilirubin score before and after stenting 
for esophageal cancer. The bars represent the mean score of  Total 
Bilirubin and the error bar indicates standard deviation. P value gives 
statistical significance of association of ‘after stenting’ scores with 
‘before stenting’ scores of Total Bilirubin.
 
 
 The Change in the bilirubin levels before stenting 4 and 8 weeks after 
stenting is statistically not significant. 
P= 0.202 and P = 0.115 respectively 
   
 
 
 
 
 
 
Table.12 Comparison of   Total Bilirubin before and after stenting 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
0.86+0.19 - - 
After 4 
weeks 
 
0.93+0.21 0.07+0.26 0.202 
After 8 weeks 
 
1.65+2.28 0.79+2.21 0.115 
 
 The Change in the bilirubin levels before stenting 4 and 8 weeks after 
stenting is statistically not significant. 
P= 0.202 and P = 0.115 respectively 
  
 
 
 
 
 
Chart 10 : Comparison of SGOT score before and after stenting for 
esophageal cancer. The bars represent the mean score of SGOT and the 
error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of SGOT. 
 
The change in the SGOT levels are statistically non significant after 4 weeks 
and 8 weeks after stenting. 
       
  
 
 
 
 
 
 
Table,13:Comparison of   SGOT before and after stenting 
Timelines in 
relation to stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
36.29+6.2 - - 
After 4 weeks 
 
33.24+4.9 3.05+8.8 0.128 
After 8 weeks 
 
39.52+4.79 3.23+9.35 0.128 
 
The change in the SGOT levels are statistically non significant after 4 weeks 
and 8 weeks after stenting. 
  
 
 
 
 
 
Chart 11 : Comparison of SGPTscore before and after stenting for 
esophageal cancer. The bars represent the mean score of SGPT and the 
error bar indicates standard deviation. P value gives statistical 
significance of association of ‘after stenting’ scores with ‘before 
stenting’ scores of SGPT. 
 
The increase in SGPT levels after stenting is non significant after 4 weeks 
but it is significant after 8 weeks post stenting. 
  
 
 
 
 
 
 
Table,14: Comparison of  SGPT before and after stenting 
Timelines in 
relation to 
stenting 
Mean + SD Mean difference 
+ SD 
P value 
 
Before stenting 
33.33 - - 
After 4 
weeks 
 
36.90+12.31 3.57+15.64 0.308 
After 8 weeks 
 
44.81+6.78 11.47+7.11 <0.0001 
 
The increase in SGPT levels after stenting is non significant after 4 weeks 
but it is significant after 8 weeks post stenting. 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 In   studies conducted all over the world by comparing the   quality of 
life of patients with carcinoma esophagus before and after esophageal 
stenting, The success rate of the stenting procedure was around 80-95%, in 
most of the studies27,. 
  In our study also the procedural success rate was around  95%out of 
21 patients only one patient had the complication of stent migration, which 
needed reinsertion. 
 A prospective study conducted in the AIIMS, New Delhi, 
Madusudhan et al3.studied the improvement of quality of life after 
esophageal stenting in carcinoma esophagus , 33 patients were studied 
before and after stenting, the results were published in the year 2009.In that 
study improvement of quality of life after stenting was assessed with 
EORTC QLQ 30 OES 18 (version 3). The results were in favour of  
esophageal stenting as a palliative procedure, because the improvement of 
quality of life was statistically significant  .  
 In another study conducted byNanda Kishore Maroju et al11, in the 
department of Surgery ,JIPMER ,Pondichery. 29 patients  were deployed  
covered SEMS for malignant dysphagia in the year between 2001 -2003 , in 
the result though there was increase in pain scores ,all patients had 
significant relief of dysphagia and improvement in quality of life,  
 
 
 In our study also, we observed similar results, like  the dysphagia 
relief is immediate and statistically significant, after stenting . The pain score 
initially got worsened  after stenting but later it showed improvement. The 
general health score also improved following stenting, the improvement in 
score were also statistically significant.   
 A retrospective study conducted in Ataturk University12,Turkey,  170 
patients treated with palliative esophageal stenting from the year 2000 to 
2008  The improvement of dysphagia was evaluated by modified Takita’s 
grading system that improved from 3.4 before the procedure to 2.6 after 
stenting , it also concludes that stenting require less frequent intervention 
after stenting, and provides significant improvement in dysphagia and 
quality of life . 
 
 Sahlgrenska University Hospital 13 conducted a randomized controlled 
clinical trial in total of 65 patients, out of which 34 patients underwent 
SEMS insertion and the remaining  31 were treated with endoluminal 
brachytherapy , the results were published in the year 2005, the improvement 
of dysphagia was measured with EORTC QLQ 30 OES 23 questionnaire. 
Statistically Significant improvement was noted in the SEMS group. In our 
study also, the dysphagia relief is significant after 7 days, 4weeks and 8 
weeks  respectively . 
 
 
 Another study conducted by  Martin et al 8 compared the results of  
esophageal stenting  Vs.endoscopic esophageal dilatation procedures. A 
Total of 18 patients underwent stent insertion and 24 patients were treated 
only with endoscopic dilatation  strictures. The results were also in favour of 
esophageal stenting. It concluded that the use of a SEPS was safe, not only 
the dysphagia relief is significant, but also economically beneficial and cost 
effective ,compared with the failed or multiple dilatation procedures. But 
Cochrane Database ,Interventions for dysphagia in oesophageal cancer. Dai 
Y1, Li C,et al7, concluded that SEMS are safer and more effective than 
plastic stents. 
 
 In our study, the relief of dysphagia , general health related 
improvement of quality of life, and pain related improvement of quality of 
life were studied with the help of EORTC QLQ 30 OES 18 questionnaire, in 
addition to this we have studied and compared the anthropometric 
improvement like BMI, Biochemical improvement like, Hemoglobin ,Total 
proteins ,and other liver function tests, SGOT,SGPT , before and after 
stenting. 
 The dysphagia score is 6.10+1.48 before stenting ,it improved to 
12.57+2.29 after 1 week,15.05+1.74,after 4 weeks and 15.57 +1.20 after 8 
weeks. Thus the improvement of dysphagia before and after stenting is  
statistically significant.  
 
 
    The personal social health related quality of life score before stenting 
was 32.95+2.24, it improved to 26.33+3.56, after one week ,15.05+2.22 after 
4 weeks and 13.14+1.98 after 8 weeks. The improvement of health related 
quality of life is also statistically significant. 
 The pain related quality of life was 7.10+1.54 before stenting, after 
one week the pain got worsened and it increased to 10.00+1.97 .The 
worsening of pain after one week is statistically significant.After 4 weeks the 
pain related quality of life improved from the baseline score before stenting 
to 5.38,and after 8 weeks it further improved to 4.00+0.95,These 
improvements in pain related quality of life too are statistically significant. 
The improvement of BMI and Hemoglobin  4 weeks after stenting is 
statistically not significant , but  8 weeks after stenting , the improvement of  
BMI and hemoglobin are statistically significant 
 The biochemical parameters like Blood sugar, Urea are within the 
normal limits except for the diabetic patients, but the variation is statistically 
significant , before Vs 4 weeks and 8 weeks after stenting.  
           The variation in the creatinine values before and after stenting is not 
significant. 
 A statistically significant improvement is noted in the values of the 
total proteins and albumin measured at 4 weeks and 8 weeks post stenting, 
whereas the globulin improvement became significant only after 8 weeks. 
 
 
 No statistically significant changes are noted in the values of liver 
function tests like total bilirubin and SGOT, but SGPT values are found to be  
increased with statistically significant  values, 8 weeks after stenting, due to 
unexplained reasons. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION: 
 There is a definite and statistically significant  improvement in the relief 
of dysphagia after esophageal stenting in carcinoma esophagus . 
 There is a significant improvement in the personal, social health related 
quality of life, after the esophageal stenting in carcinoma esophagus. 
 There is an initial  deterioration of pain score at the first week ,then 
followed by statistically significant improvement in the pain related 
quality of life after stenting, in carcinoma esophagus. 
 Though there is improvement in the   anthropometrical (BMI) score after 
stenting, the improvement is statistically non significant. 
 Though there is  improvement in the hemoglobin level after stenting, the 
improvement is statistically non significant. 
 There is definite andstatistically significant improvement in the values of 
total protein and and albumin after stenting  
 The improvement  in the values of Globulin in statistically non 
significant after 4 weeks , but the improvement is statistically significant 
in  8 weeks after stenting.  
 The changes in the values of SGOT 4 weeks and 8 weeks after stenting 
are statistically non significant. 
 The SGPT values increase statistically non significant in the first 4 
weeks and significant in the 8 weeks after stenting.  
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